Theravance Biopharma Inc. (NASDAQ:TBPH) was up 3% on Friday . The stock traded as high as $22.96 and last traded at $22.92, with a volume of 236,799 shares. The stock had previously closed at $22.26.

Several equities research analysts recently weighed in on TBPH shares. Zacks Investment Research downgraded Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Tuesday, April 19th. Bank of America Corp. downgraded Theravance Biopharma from a “buy” rating to a “neutral” rating in a report on Thursday, May 5th. Leerink Swann started coverage on Theravance Biopharma in a report on Thursday, May 12th. They set an “outperform” rating and a $26.00 price target for the company. Finally, Guggenheim started coverage on Theravance Biopharma in a report on Monday, June 20th. They set a “buy” rating and a $30.00 price target for the company. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $24.75.

The company’s 50 day moving average price is $22.94 and its 200-day moving average price is $19.50. The firm’s market capitalization is $1.09 billion.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($1.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.96) by $0.14. The business earned $18.40 million during the quarter, compared to the consensus estimate of $18.69 million. On average, analysts expect that Theravance Biopharma Inc. will post ($4.24) EPS for the current year.

A hedge fund recently raised its stake in Theravance Biopharma stock. OppenheimerFunds Inc. raised its stake in Theravance Biopharma Inc. (NASDAQ:TBPH) by 1.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,103,485 shares of the biopharmaceutical company’s stock after buying an additional 12,120 shares during the period. OppenheimerFunds Inc. owned about 2.92% of Theravance Biopharma worth $18,086,000 as of its most recent filing with the SEC.

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.